1
项与 Dendritic Cell Vaccine(National Health Research Institutes, Taiwan) 相关的临床试验Personalized Neoantigen Derived Dendritic Cell-Based Immunotherapy as Cancer Treatment
Tumor lysate or carcinoembryonic antigen (CEA) derived DCs-based therapy is safe and can elicites remarkable T-cell responses but mostly did not really transfer into significant clinical benefit. One possible reason is the lack of effective antigen and the immunosuppressive microenvironment. Now we are exploring another new strategy, prediction of neoantigen for priming DCs as cell-based therapy with or without booster of anti-VEGF/anti-PD-1.
100 项与 Dendritic Cell Vaccine(National Health Research Institutes, Taiwan) 相关的临床结果
100 项与 Dendritic Cell Vaccine(National Health Research Institutes, Taiwan) 相关的转化医学
100 项与 Dendritic Cell Vaccine(National Health Research Institutes, Taiwan) 相关的专利(医药)
100 项与 Dendritic Cell Vaccine(National Health Research Institutes, Taiwan) 相关的药物交易